Abstract
Dry powder inhalers (DPIs) are the latest development in inhaled drug therapy. They deliver the drug as a dry powder in a suitable formulation which can be drug only, or contain excipients, and has excellent stability compared to drug solutions or suspensions. The formulation has to enable reproducible dose delivery and dispersion into an appropriate aerosol for inhalation, for which the energy of the inhaled air stream is used. DPIs can either be single dose, multiple unit dose or multi-dose, the latter having a bulk container and an appropriate powder measuring system to be operated by the patient. DPIs can deliver much higher doses than MDIs, and using them is considerably less a burden for the patient than nebulization. Innovative inhaler design and particle engineering make it possible to achieve high lung doses with DPIs, whereas losses due to inhaler retention and waste to the environment can be limited.
| Original language | English |
|---|---|
| Title of host publication | Inhaled Medicines |
| Subtitle of host publication | Optimizing Development through Integration of In Silico, In Vitro and In Vivo Approaches |
| Editors | Stavros Kassinos, Per Bäckman, Joy Conway, Anthony J. Hickey |
| Publisher | Elsevier |
| Chapter | 5 |
| Pages | 99-146 |
| Number of pages | 48 |
| ISBN (Electronic) | 978-0-12-814974-4 |
| DOIs | |
| Publication status | Published - 2021 |